p53 in prostate cancer: frequent expressed transition mutations.

BACKGROUND Carcinoma of the prostate is the second most common cause of cancer deaths in men. Little is known about the pathogenesis of this disease and the molecular genetic events that contribute to its development. Molecular studies have begun to reveal biologic characteristics of this disease, notably, the loss of genetic material as determined by studies of restriction fragment length polymorphism, oncogene activation, and production and response to growth factors. PURPOSE Our goal was to characterize p53 gene mutations in human carcinoma of the prostate and to analyze base-pair changes within the coding regions of p53 mRNA (exons 4 through 11). METHODS Forty-four prostate tissue specimens and four metastatic lesions were obtained from 48 prostate carcinoma patients who had surgical resection. RNA was either immediately extracted or the specimens were snap-frozen in liquid N2 and stored at -70 degrees C until used. Total RNA was extracted from tumor specimens. Expression of p53 was analyzed by polymerase chain reaction (PCR) analysis of mRNA (RNA/PCR). Following confirmation of the RNA/PCR products by Southern blotting, quantitation of message levels was performed by laser densitometry. Absolute area integrations of the curves representing each tissue were then compared after adjustment for the housekeeping gene c-N-ras. Two overlapping regions (exons 4-6 and 6-11) were examined by a nonisotopic PCR single-strand conformation polymorphism (SSCP) analysis system. All specimens displaying SSCP abnormalities were sequenced in both directions to confirm the findings. RESULTS Of the 48 prostate specimens, three (6%) (two primary and one metastatic) displayed nearly undetectable expression of p53 mRNA (samples PS-70, L113, and PS-95) and 17 (35%) of 48 expressed mutant p53 mRNA encoding amino acid substitutions within exons 4-11 (14 of 17) and/or deletions within the p53 transcripts (three of 17). Overall, the frequency of p53 gene abnormalities that would result in altered protein expression was 20 (42%) of 48 in the tissue samples from prostate carcinoma patients. Nucleotide base-pair transitions of A-->G or T-->C were the most frequent. CONCLUSIONS p53 mutations are common in prostate cancer. The patterns of p53 gene mutations are dramatically different from data obtained on other cancers and indicate the possible involvement of a carcinogenic agent(s). IMPLICATIONS Further studies are required to determine the biologic role of p53 gene alterations in the development and progression of this disease and to determine whether p53 mutations can be useful as prognostic markers or for the selection of better treatments for prostate cancer patients.

[1]  R. deVere White,et al.  p53 mutations in benign prostatic hyperplasia. , 1993, Journal of the National Cancer Institute.

[2]  A. Hogg,et al.  Molecular mechanisms of oncogenic mutations in tumors from patients with bilateral and unilateral retinoblastoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Ziegler,et al.  Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[5]  A. Sandberg.  Chromosomal abnormalities and related events in prostate cancer. , 1992, Human pathology.

[6]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[7]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[8]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Merlo,et al.  Mutations in the p53 gene in primary human breast cancers. , 1991, Cancer research.

[10]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[11]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[12]  M. Pike,et al.  From gene to carcinogen: a rapidly evolving field in molecular epidemiology. , 1991, Cancer research.

[13]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[14]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[15]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[16]  D. Brachman,et al.  Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes , 1991, Journal of surgical oncology.

[17]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[18]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[20]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[21]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[22]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[23]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[24]  D. Roth,et al.  Mechanisms of nonhomologous recombination in mammalian cells , 1985, Molecular and cellular biology.

[25]  A. Albertini,et al.  On the formation of spontaneous deletions: The importance of short sequence homologies in the generation of large deletions , 1982, Cell.

[26]  R. Vollmer,et al.  Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. , 1977, Cancer research.

[27]  G. Thomas,et al.  Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. , 1993, Oncogene.

[28]  W. Isaacs,et al.  Genetic changes associated with prostate cancer in humans. , 1991, Cancer surveys.

[29]  M. Inouye,et al.  Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday. , 1966, Cold Spring Harbor symposia on quantitative biology.